Extreme Heat Is Killing European Workers Despite Government Efforts
At the end of the shift, at around 9:30pm, she walked back home and asked her elderly mother to prepare dinner because she wasn't feeling well. She also messaged a friend and told him she felt cramps in her arms, chest and neck, her brother-in-law Manuel Ceacero told Bloomberg Green.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
Almirall selects second target in AI Drug Creation collaboration Expanded collaboration builds on Absci's successful molecule design for difficult‑to‑drug targets in the first stage of the collaboration with Almirall BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the expansion of their ongoing AI Drug Discovery collaboration with Almirall's selection of a second target aimed at dermatological indications. The expansion of the collaboration follows the successful delivery of AI-designed, functional antibody leads against a difficult-to-drug target—the first target addressed within the initial collaboration between Almirall and Absci. The collaboration, originally announced in November 2023, combines Absci's Integrated Drug Creation™ platform with Almirall's dermatology expertise to accelerate the development of novel and breakthrough therapeutics for chronic and debilitating skin diseases. 'Using advanced AI capabilities to design therapeutic candidates against historically challenging disease targets is a highly promising approach and Absci´s de-novo AI platform capabilities have already demonstrated early success' said Dr. Karl Ziegelbauer, Chief Scientific Officer at Almirall. 'We are pleased to expand our collaboration as we continue to harness AI to help us develop innovative treatments for patients living with severe skin conditions.' Under the terms of the collaboration, Absci is leveraging its generative AI platform combined with its wet lab capabilities to design and validate therapeutic candidates, while Almirall leads the preclinical and clinical development programs of those candidates. Absci is eligible to receive up to approximately $650 million in upfront, R&D, and post-approval milestone payments across both programs, plus royalties on potential product sales. 'The progress in our collaboration is a testament that AI de novo drug design is a successful approach to unlock novel biology where traditional drug discovery approaches have failed,' said Sean McClain, Founder and CEO of Absci. 'We're proud of this milestone and excited to deepen our collaboration with Almirall with the goal of bringing a new generation of AI-created therapeutics for dermatology patients.' The expansion of the collaboration to include a second program is at the heart of the shared commitment of both companies - to accelerate innovation in dermatology by using generative AI to enable new therapeutic approaches. About Almirall Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients´ needs. Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2024: €990 MM, over 2000 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries. For more information, please visit Corporate Communications: Investor Relations Phone: +34 93 291 35 08 Phone: (+34) 93 291 30 87 About Absci Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci's approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics. These include ABS-101, a potentially best-in-class antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube. Absci Media Contactpress@ Absci Investor ContactAlex KhanVP, Finance & Investor Relationsinvestors@
Yahoo
5 days ago
- Yahoo
Barcelona star has begun ignoring the club's phone calls
Barcelona star Marc-André ter Stegen is no longer responding to the club's efforts to make contact with he and his entourage. That's according to Mundo Deportivo, who have today provided a fresh insight into the situation. Ter Stegen's tense situation in Catalunya's capital has of course continued to dominate the headlines across Spain over the last 24 hours. This comes after a fresh and altogether significant development in the saga was forthcoming. This came by way of Ter Stegen refusing to sign the club's medical report, regarding his recent surgery and expected length of absence. As a result, Barcelona are currently unable to utilise their experienced shot-stopper's wages to register one or more of the club's summer signings. And as alluded to above, if the latest word stemming from the media today is anything to go by, then the situation appears to be reaching the point of no return. As per a report from : 'Ter Stegen didn't answer calls from the club's doctors on Monday to ask him to sign the medical report, and it was one of his agents who ultimately informed the club that he wouldn't do so.' Communication has completely broken down between the two parties, meaning a resolution being found is beginning to look increasingly unlikely. Conor Laird – GSFN
Yahoo
6 days ago
- Yahoo
👟 The silent mistake at Valdebebas that could lead to injuries
In the sophisticated gym of Valdebebas, where every minute of training is optimized, a silent practice has become habitual among many Real Madrid players: doing strength exercises with highly cushioned running shoes. What seems like a minor wardrobe choice may be directly affecting the quality of strength training and, in the worst-case scenario, increasing the risk of injury. 👟 The wrong footwear: more common than it seems According to the photos published by the club on its official channels, a good part of the squad does squats, lunges, deadlifts, or plyometric exercises with shoes designed for running long distances, not for weightlifting. These shoes, known for their high cushioning and soft sole, are designed to absorb impacts, but not to provide stability, as even the manufacturers themselves recognize. In a graphic way, using this type of footwear for strength training is like lifting weights on a mattress. 🤕 What's at stake? Wasted performance: the strength developed in exercises like deadlifts or squats depends on a stable base. If the shoe absorbs part of that force, the player wastes part of the benefits. Risk of functional injuries: the instability of a soft shoe can lead to micromovements in ankles, knees, or hips. In elite athletes who already carry high volumes of load, this can result in tendinitis, sprains, or chronic back overloads. Postural misalignment: many running shoes have elevated heels and curved soles. This modifies the athlete's natural posture, something especially delicate in exercises where the spine and pelvis must be kept aligned and firm. ✅ What should they be using? The ideal is to use weightlifting shoes or flat, firm shoes like CrossFit, such as those used by Carvajal, Rudiger, or Mbappé in the photos disseminated by Real Madrid. 👍🏻 Does training with unstable shoes provide benefits? Training strength with unstable shoes can have certain benefits for the professional footballer, but only if done in a specific, controlled, and targeted manner. For example, training with controlled instability improves motor control and strengthens ankles, knees, and hips, which can be beneficial in real game situations. Real Madrid has won Champions Leagues, leagues, and super cups by taking care of every minor detail. But in the high-performance environment, small margins create enormous differences. And something as seemingly trivial as gym footwear can be the difference between a brilliant season... or an injury that changes everything. This article was translated into English by Artificial Intelligence. You can read the original version in 🇪🇸 here. 📸 PIERRE-PHILIPPE MARCOU - AFP or licensors
